Sander Wuyts, PhD 🧬
@swuyts.bsky.social
Helping scientists find the epitope specificity of their T-cell receptors at @immunewatch.bsky.social (www.immunewatch.com)
Scientist on an entrepreneurial journey
PhD in bioinformatics and microbiology
Ex-Bork (EMBL) and Lebeer lab
Scientist on an entrepreneurial journey
PhD in bioinformatics and microbiology
Ex-Bork (EMBL) and Lebeer lab
That's a very nice way of putting it :)
November 11, 2025 at 7:19 PM
That's a very nice way of putting it :)
Or on Spotify:
open.spotify.com/episode/00h1...
open.spotify.com/episode/00h1...
The Repertoire Room: Episode 3 - Arman Aksoy (Obsidian Therapeutics)
Spotify video
open.spotify.com
October 28, 2025 at 12:52 PM
Or on Spotify:
open.spotify.com/episode/00h1...
open.spotify.com/episode/00h1...
Among many things, in this episode we discuss:
- Obsidian's lead program, OBX-115, a modified TIL cell therapy
- The critical role of TCR sequencing in profiling infusion products, tracking clonotypes, and identifying biomarkers for therapy response.
Listen/View here:
youtu.be/J41q0fUqeVo?...
- Obsidian's lead program, OBX-115, a modified TIL cell therapy
- The critical role of TCR sequencing in profiling infusion products, tracking clonotypes, and identifying biomarkers for therapy response.
Listen/View here:
youtu.be/J41q0fUqeVo?...
The Repertoire Room: Episode 3 - Arman Aksoy (Obsidian Therapeutics)
YouTube video by ImmuneWatch
youtu.be
October 28, 2025 at 12:52 PM
Among many things, in this episode we discuss:
- Obsidian's lead program, OBX-115, a modified TIL cell therapy
- The critical role of TCR sequencing in profiling infusion products, tracking clonotypes, and identifying biomarkers for therapy response.
Listen/View here:
youtu.be/J41q0fUqeVo?...
- Obsidian's lead program, OBX-115, a modified TIL cell therapy
- The critical role of TCR sequencing in profiling infusion products, tracking clonotypes, and identifying biomarkers for therapy response.
Listen/View here:
youtu.be/J41q0fUqeVo?...
Oh great! And why? Because of the relative smaller size compared to ESMO?
October 27, 2025 at 7:54 PM
Oh great! And why? Because of the relative smaller size compared to ESMO?
Vooral dus een anekdotische les gebaseerd op eigen ervaring:)
October 3, 2025 at 10:51 AM
Vooral dus een anekdotische les gebaseerd op eigen ervaring:)
October 3, 2025 at 10:50 AM
2) Solving a scientific problem does not equal market opportunities.
Bv. ImmuneWatch. Sterke tech maar lang zoeken naar product-market fit. Na eerst diagnostiek te exploreren lijken we die gevonden te hebben met software/service model.
3) Lijst van frameworks die mij goed hebben geholpen
Bv. ImmuneWatch. Sterke tech maar lang zoeken naar product-market fit. Na eerst diagnostiek te exploreren lijken we die gevonden te hebben met software/service model.
3) Lijst van frameworks die mij goed hebben geholpen
October 3, 2025 at 10:50 AM
2) Solving a scientific problem does not equal market opportunities.
Bv. ImmuneWatch. Sterke tech maar lang zoeken naar product-market fit. Na eerst diagnostiek te exploreren lijken we die gevonden te hebben met software/service model.
3) Lijst van frameworks die mij goed hebben geholpen
Bv. ImmuneWatch. Sterke tech maar lang zoeken naar product-market fit. Na eerst diagnostiek te exploreren lijken we die gevonden te hebben met software/service model.
3) Lijst van frameworks die mij goed hebben geholpen
Is het not done om hier naar Linkedin te linken?🤔
Heb daar even drie take aways uitgeschreven:
1) Stay Flexible
Bv. Kultured: Succesvolle Krautfunding en initiele B2C verkoop maar verdere groei viel tegen. Pivot naar B2B lijkt way to go.
Heb daar even drie take aways uitgeschreven:
1) Stay Flexible
Bv. Kultured: Succesvolle Krautfunding en initiele B2C verkoop maar verdere groei viel tegen. Pivot naar B2B lijkt way to go.
October 3, 2025 at 10:50 AM
Is het not done om hier naar Linkedin te linken?🤔
Heb daar even drie take aways uitgeschreven:
1) Stay Flexible
Bv. Kultured: Succesvolle Krautfunding en initiele B2C verkoop maar verdere groei viel tegen. Pivot naar B2B lijkt way to go.
Heb daar even drie take aways uitgeschreven:
1) Stay Flexible
Bv. Kultured: Succesvolle Krautfunding en initiele B2C verkoop maar verdere groei viel tegen. Pivot naar B2B lijkt way to go.
OMG 😭 How could I have missed this
October 1, 2025 at 6:00 PM
OMG 😭 How could I have missed this
Lol, indeed not something everyone can say 😃
September 17, 2025 at 12:16 PM
Lol, indeed not something everyone can say 😃
First PhD students graduating... What a milestone for the lab!
August 19, 2025 at 7:01 AM
First PhD students graduating... What a milestone for the lab!